998 related articles for article (PubMed ID: 16678649)
1. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
5. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
7. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.
McGough JJ; Biederman J; Wigal SB; Lopez FA; McCracken JT; Spencer T; Zhang Y; Tulloch SJ
J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):530-8. PubMed ID: 15908835
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
11. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
Brams M; Mao AR; Doyle RL
Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
[TBL] [Abstract][Full Text] [Related]
12. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
15. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kando JC; King TR; Pardo A; Herman BK
J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):2-8. PubMed ID: 30575407
[TBL] [Abstract][Full Text] [Related]
16. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
Silva RR; Brams M; McCague K; Pestreich L; Muniz R
Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
[TBL] [Abstract][Full Text] [Related]
17. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.
McCracken JT; Biederman J; Greenhill LL; Swanson JM; McGough JJ; Spencer TJ; Posner K; Wigal S; Pataki C; Zhang Y; Tulloch S
J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):673-83. PubMed ID: 12921475
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
Faraone SV; Childress AC; Gomeni R; Rafla E; Kando JC; Dansie L; Naik P; Pardo A
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):14-19. PubMed ID: 36730749
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]